Site search

Clear filter
3042 results for '' found
Characterization of Mid-term Post Market Clinical Follow Up of GORE® TAG® Thoracic Branch Endoprosthesis Facilitated Aortic Arch and Descending Aorta Intervention (NCT06507865)
Characterization of Mid-term Post Market Clinical Follow Up of GORE® TAG® Thoracic Branch Endoprosthesis Facilitated Aortic Arch and Descending Aorta Intervention (NCT06507865)
/
Assessment of Long Term, Endovascular AAA Intervention using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis (NCT06218875)
Assessment of Long Term, Endovascular AAA Intervention using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis (NCT06218875)
/
A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Following Treatment with LY3439539 in Participants with Symptomatic Alzheimer
A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Following Treatment with LY3439539 in Participants with Symptomatic Alzheimer
/
The INCremental dialysis to improve Health outcomes in people starting Haemodialysis [INCH-HD] study: a randomised controlled trial (NCT04932148)
The INCremental dialysis to improve Health outcomes in people starting Haemodialysis [INCH-HD] study: a randomised controlled trial (NCT04932148)
/
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D [ON/OFF] Inhibitor, as Monotherapy and with Cetuximab, in Patients with Metastatic KRAS G12D-Mutated Pancreatic Cancer [TARGET-D 201] (NCT0764
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D [ON/OFF] Inhibitor, as Monotherapy and with Cetuximab, in Patients with Metastatic KRAS G12D-Mutated Pancreatic Cancer [TARGET-D 201] (NCT0764
/
A Phase 2 Open-label Study of VS-7375, an Oral KRAS G12D [On/Off] Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G
A Phase 2 Open-label Study of VS-7375, an Oral KRAS G12D [On/Off] Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G
/
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with ZL-1310 with or without Anti-PD-L1 in Participants with Small Cell Lung Cancer (N
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with ZL-1310 with or without Anti-PD-L1 in Participants with Small Cell Lung Cancer (N
/
RandOmised Arthroplasty infection worlDwide Multidomain Adaptive Platform trial (NCT06771050)
RandOmised Arthroplasty infection worlDwide Multidomain Adaptive Platform trial (NCT06771050)
/
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combina
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combina
/
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibito
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibito
/
1 2 3